Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | RXRA | P19793 | 2/20 | 0.57 |
| ▸ | RXRB | P28702 | 2/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12492047 | 0.87 | NR4A2 (0.55) | NR4A2RXRARXRBPKMPLA2G4B | |
| SCHEMBL27697782 | 0.85 | NR4A2 (0.54) | NR4A2RXRARXRBPKMPLA2G4B | |
| SCHEMBL5789164 | 0.85 | L3MBTL1 (0.63) | POLBRAB9ASMN1; SMN2HTT | |
| SCHEMBL17176884 | 0.84 | PKM (0.60) | NR4A2RXRARXRBPKMPLA2G4B | |
| SCHEMBL11693473 | 0.84 | RXRA (0.53) | NR4A2RXRARXRBPKMPLA2G4B | |
| SCHEMBL12492666 | 0.84 | CA1 (0.53) | NR4A2RXRARXRBPKMPLA2G4B | |
| SCHEMBL14033180 | 0.84 | PPARA (0.61) | MAPK1RAB9ASMN1; SMN2HTT | |
| SCHEMBL18997044 | 0.83 | PARP10 (0.65) | TSHRCA1CA2USP2 | |
| SCHEMBL468288 | 0.81 | MAPT (0.49) | NR4A2RXRARXRBCA1CA2 | |
| SCHEMBL13366190 | 0.81 | MAPT (0.68) | CA1CA2NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372885-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-02-12 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2010-05-13 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120872-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, OTC, AOX1 | NR4A2 1408/4885RXRA 444/4885RXRB 529/4885 |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | NR4A2 995/4885RXRA 732/4885RXRB 546/4885 |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | NR4A2 3133/4885RXRA 2656/4885RXRB 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.